A Comprehensive Narrative Review on Novel Treatment Therapies of Diabetic Retinopathy

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycaemia and progressive microvascular and macrovascular complications. Among these, diabetic retinopathy (DR) remains a leading cause of preventable vision impairment globally. With its increasing prevalence, there is a growing emphasis on developing multidisciplinary, mechanism-driven therapeutic strategies to improve patient outcomes. To critically evaluate emerging treatment modalities for diabetic retinopathy, with a particular focus on anti-VEGF therapies and recent advancements in nano-based drug delivery systems. A comprehensive literature review was conducted using PubMed, Scopus, Web of Science, EMBASE, and Google Scholar. Studies published between 2000 and 2024 were screened and analysed, with an emphasis on innovations in anti-VEGF therapeutics and the application of nanotechnology to improve drug stability, bioavailability, and targeted retinal delivery. Anti-VEGF agents, such as ranibizumab, bevacizumab, and aflibercept, remain fundamental to DR management by suppressing pathological neovascularisation and vascular permeability. Despite their effectiveness, treatment challenges - including variable patient response, recurrence, and the need for frequent intravitreal injections - limit long-term success. Recent advances in nanotechnology, particularly nanomicelle-based formulations, demonstrate potential to enhance drug solubility, prolong intraocular retention, and improve targeted delivery to retinal tissues. The integration of nanotechnology with established anti-VEGF treatments may address key limitations of current DR therapy. By improving pharmacokinetics and enabling sustained release, nano-enabled formulations could reduce treatment burden and enhance therapeutic consistency. However, clinical translation remains dependent on rigorous in vivo validation, safety profiling, and standardized manufacturing protocols. Combining advanced anti-VEGF therapies with innovative nano-delivery platforms represents a promising direction for the future management of diabetic retinopathy. These approaches may offer superior efficacy, reduced adverse effects, and improved treatment adherence. Large-scale, long-term clinical trials are crucial to confirm their therapeutic value and support their incorporation into routine clinical practice.